Chemcrux Enterprises Ltd.

Chemcrux Enterprises Ltd.

78.00
INR
-2.76
(-3.42%)
2.77EPS
32.43P/E
1.33BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
10.54
13.23
13.58
19.59
14.22
27.65
27.61
36
55.38
54.54
38.72
38.91
40.55
57.65
Basic EPS, GAAP
0.29
0.57
1.17
1.72
1.6
6.29
7.19
6.03
10.03
9.7
5.7
2.64
2.52
2.77
Free Cash Flow per Basic Share
0.27
0.55
-0.12
1.61
2.36
5.44
3.73
1.74
3.08
2.47
-5.37
-0.54
5.88
- -
Dividend per Share
- -
- -
0.03
0.05
0.1
0.1
1.41
0.33
0.67
2
2
1
1
- -
Book Value per Share
3.91
4.43
5.79
8.42
9.92
16.11
21.89
27.52
36.93
44.84
48.79
50.39
51.9
- -
Tangible Book Value per Share
3.91
4.43
5.79
8.42
9.92
16.11
21.89
27.51
36.89
44.83
48.78
50.3
51.81
- -
Basic Weighted Avg Shares
15
15
15
9
15
15
15
15
15
15
15
15
15
15
Sales/Revenue/Turnover
156
196
201
171
211
409
409
533
820
808
573
576
601
861
Operating Margin (%)
6.74
8.48
13.38
16.96
20.19
32.03
33.55
21.28
23.28
24.04
19.56
10.46
10.73
8.68
Depreciation Expense
5
5
5
6
7
13
12
12
16
20
23
32
47
47
Net Income, GAAP
4
8
17
15
24
93
106
89
149
144
84
39
37
41
Effective Tax Rate (%)
32.24
34.81
29.34
47.51
41.55
24.56
24.95
25.83
25.55
26.92
26.13
32.07
29.37
33.52
Profit Margin (%)
2.78
4.31
8.64
8.76
11.22
22.75
26.03
16.75
18.12
17.78
14.73
6.79
6.21
4.81
Working Capital
6
13
16
49
63
143
176
212
287
414
369
263
220
- -
LT Debt
10
11
8
9
18
20
10
16
17
112
223
287
221
- -
Total Equity
58
66
86
125
147
239
324
408
547
664
723
746
769
- -
Return on Invested Capital (%)
4.7
8.97
16.07
10.76
13.19
36.81
29.85
20.17
24.73
18.17
8.68
3.83
3.99
- -
Return on Capital (%)
8.02
12.12
18.43
12.32
14.53
42.07
35.58
23.44
27.89
20.42
9.99
4.72
5.2
- -
Return on Common Equity (%)
7.78
13.69
22.98
14.24
17.4
48.34
37.83
24.42
31.14
23.72
12.18
5.33
4.93
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
123
- -
LT Borrowings
- -
217
- -
LT Finance Leases
- -
3
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
1,585
974
1,333

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
463
- -
Cash, Cash Equivalents & STI
- -
183
- -
Accounts Receivable, Net
- -
189
- -
Inventories
- -
61
- -
Total Current Liabilities
- -
243
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
123
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.8%
14.13%
2.99%
Free Cash Flow
-221.17%
-307.08%
-1,184.28%
Net Income, GAAP
29.97%
-7.31%
-4.66%
Sales/Revenue/Turnover
16.08%
5.59%
4.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
171
178
194
157
576
2026
165
177
221
243
601
2027
219
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.84
0.77
0.89
0.14
2.64
2026
0.06
0.14
1.06
1.25
2.52
2027
0.34
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
1
2027
- -
- -
- -
- -
- -

Company Description

CEO
Sanjaybhai Yashawantrao Marathe
Full Time Employees
99
Sector
Process industries
Industry
Chemicals: major diversified
Address
330, Trivia Complex Ankleshwar GU India 390007
IPO Date
Mar 28, 2017
Business
Chemcrux Enterprises Limited manufactures specialty chemical intermediates for pharmaceuticals, dyes and pigments industries through advanced processes including high pressure oxidation, nitration, chlorosulphonation and amidation. The company produces a diverse range of products such as 2-chloro benzoic acid, 3-chloro benzoic acid, 4-chloro benzoic acid, 3-nitro benzoic acid, 4-nitro benzoic acid, 3-nitro salicylic acid, 5-nitro salicylic acid, various dichloro benzoic acids including 2,4-dichloro benzoic acid, 2,3-dichloro benzoic acid and 2,6-dichloro benzoic acid, 4-chloro 3-nitro benzoic acid, 2-chloro 5-nitro benzoic acid, 2-chloro 3-nitro benzoic acid, lasamide, aceturic acid, arabonic acid sodium salt, 4-chloro benzoic acid-3-sulfonamide, BPEA sulfonamide, para chloro benzoyl chloride, ortho chloro benzoyl chloride, 2,4-dichloro benzoyl chloride and 2,3-dichloro benzoyl chloride. Founded in 1983 and headquartered in Vadodara, Gujarat, India, Chemcrux operates primarily from facilities in Ankleshwar, Gujarat, serving multinational pharmaceutical organizations in India and exporting to various countries worldwide. In 2025, the company acquired an additional 50% equity stake in Kalichem Private Limited, converting it into a wholly owned subsidiary effective February 27 and ceasing the prior joint venture structure. It also entered into an exclusive purchase and marketing agreement with Deepak Nitrite Limited for para nitro benzoic acid and a strategic collaboration with Deepak Nitrite to enhance supply chain efficiency. Chemcrux maintains ISO 9001:2008 and ISO 14001:2004 certifications, focusing on custom synthesis for active pharmaceutical ingredients, dyes and pigments sectors.